NCT07874009|Enrolling By Invitation
Loading search results
Sponsor study identifier
interventional
26
1 country
1
Study Start
October 1, 2026
Actual (reported)Primary Completion
October 30, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
October 30, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
To evaluate and compare the effect of adjuvant oral magnesium supplementation combined with Botulinum Toxin Type A versus Botulinum Toxin Type A alone on the reduction of millimeter gingival display and the duration of clinical effectiveness in patients with excessive gingival display
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
October 30, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
October 1, 2026
Actual (reported)October 8, 2026
Actual (reported)October 14, 2026
Actual (reported)October 30, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
October 30, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Change in gingival display
Change in gingival display BY Ruler in Millimeters
at 6 weeks
Assessment of Pain by visual analogue scale
at 6 weeks
Oral Supplement group: Oral Magnesium Glycinate capsules (300 mg elemental magnesium daily, single or divided dose taken with meals). Supplementation starts 4 weeks prior to BoNT-A injection (Day -28) to achieve intracellular steady-state repletion and continues for 4 weeks post-injection (through Day 28), totaling 8 consecutive weeks (56 days) of daily intake.
Botulinum toxin type A Injection Alone group: Botulinum toxin type A Injection Alone group : BoNT-A Injection Alone (Day 0): Identical administration protocol (2.5 Units per side bilaterally at the Yonsei Point, total 5.0 Units) delivered by the same experienced operator without any oral supplementation
Oral Supplement: Oral Magnesium Glycinate capsules (300 mg elemental magnesium daily, single or divided dose taken with meals). Supplementation starts 4 weeks prior to BoNT-A injection (Day -28) to achieve intracellular steady-state repletion and continues for 4 weeks post-injection (through Day 28), totaling 8 consecutive weeks (56 days) of daily intake
BoNT-A Injection Alone (Day 0): Identical administration protocol (2.5 Units per side bilaterally at the Yonsei Point, total 5.0 Units) delivered by the same experienced operator without any oral supplementation.
Cairo University
Cairo, Egypt
Maie Esmaiel, lecturer
Cairo University
First Submitted
October 8, 2026
First Posted
October 14, 2026
Study Start
October 1, 2026
Actual (reported)Primary Completion
October 30, 2027
EstimatedRegistry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
Planned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
October 30, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
October 14, 2026
Record last verified: 2026-10
It will be available if it needed
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: